IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 nov. 2021 16h15 HE
|
IN8bio, Inc
Closed initial public offering raising net proceeds after expenses of $32.3 million.Added two new independent Directors and increased diversity across our Board of Directors.Completed patient dosing...
IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO
04 nov. 2021 08h00 HE
|
IN8bio, Inc
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme
27 oct. 2021 07h00 HE
|
IN8bio, Inc
Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma MGMT-modified gamma-delta T...
IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021
04 oct. 2021 16h15 HE
|
IN8bio, Inc
NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
10 sept. 2021 16h15 HE
|
IN8bio, Inc
First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100Data presentations made at ASCO and AACR$40M initial public offering (IPO) in August 2021 to fund continuing operations ...
IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
30 août 2021 07h00 HE
|
IN8bio, Inc
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
11 août 2021 08h00 HE
|
IN8bio, Inc
The first cohort has completed dosing with IN8bio’s donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs)...
IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors
04 août 2021 08h00 HE
|
IN8bio, Inc
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
IN8bio Announces Pricing of Initial Public Offering
30 juil. 2021 07h00 HE
|
IN8bio, Inc
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell...
IN8bio Launches Proposed Initial Public Offering
22 juil. 2021 07h52 HE
|
IN8bio, Inc
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma delta...